Research Article

Rapid Screening of Potential Phosphodiesterase Inhibitors from the Roots of *Ilex pubescens* Hook. et Arn. Using a Combination of Ultrafiltration and LC-MS

Zichen Liu,¹ Zongtao Lin,² Shizhong Chen,³ Lingjun Wang,¹ and Shaoxiang Xian¹

¹Guangzhou Key Laboratory of Chinese Medicine Prevention and Treatment of Chronic Heart Failure, The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510407, China

²Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 28163, USA

³School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

Correspondence should be addressed to Shaoxiang Xian; shaoxiangx@hotmail.com

Received 22 November 2016; Revised 15 February 2017; Accepted 12 March 2017; Published 23 March 2017

Academic Editor: Hyunsu Bae

Copyright © 2017 Zichen Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The cyclic nucleotide phosphodiesterase (PDE) plays an important role in regulating the levels of second messenger molecules cAMP and cGMP. Various PDE inhibitors have been successfully developed into drugs for targeted diseases. In addition, PDE inhibitors can also be found in different foods and natural medicines. In this study, ultrafiltration liquid chromatography–diode-array detector–electrospray ionization–ion-trap–time-of-flight–mass spectrometry (ultrafiltration LC–DAD–ESI–IT–TOF–MS) was applied to screen PDE inhibitors from the roots of *Ilex pubescens* Hook. et Arn. As a result, 11 major compounds were identified in *I. pubescens* roots, with nine compounds as potential PDE inhibitors, among which five were further confirmed to be active against PDEI and PDE5A dose-dependently in vitro, with ilexosaponin A₁ and ilexosaponin B₂ being the strongest. HPLC quantification of these bioactive compounds suggested that they are major components in the plant. The results demonstrate that ultrafiltration LC–DAD–ESI–IT–TOF–MS is an efficient method for rapid screening of PDE inhibitors from natural medicines.

1. Introduction

Phosphodiesterase (PDE) hydrolyzes phosphodiester to phosphomonoesters and is expressed in various tissues and organs intracellularly and extracellularly [1]. The cyclic nucleotide phosphodiesterases, both cAMP and cGMP, play important roles in cardiac physiology and pathology and can be hydrolyzed specifically by PDEs [2–4]. In addition, seven of the 11 PDE family members are known to be expressed in the heart tissue, suggesting the importance of PDEs to the cardiac system. PDEs regulate many crucial processes maintaining cardiac function and other pathological signaling pathways [5]. Among PDEs, PDE5 is cGMP-activated and cGMP-specific and has been a crucial target for developing treatments of cardiovascular diseases [2]. Some successful PDE5 inhibitors such as Sildenafil, Tadalafil, and Vardenafil have already been approved for erectile dysfunction and pulmonary hypertension [3, 6–8]. Encouraged by the success

and broad applications of PDE inhibitors, investigations on the novel types of PDE inhibitors have drawn increasing attentions of researchers.

Ilex pubescens Hook. et Arn. (*Maodongqing* in Chinese) is well known for its roots, which are used as a traditional Chinese medicine for the treatment of cardiovascular diseases such as coronary arterial thrombosis [9, 10], heart failure [11], stroke [12], and thromboangiitis obliterans [13] for a long time. In addition, the leaves of *I. pubescens* are a herbal tea [14] and *Radix Ilicis Pubescentis* can be used as an ingredient for functional food or soup. *I. pubescens* contains various chemical components including flavonoids, triterpene saponins, lignans, and phenolic acids [15]. Our previous study has shown that *Radix Ilicis Pubescentis* extract dose-dependently improved the cardiac function and ventricular remodeling on rats with chronic heart failure [16]. And our preliminary study additionally revealed that the extract from *Radix Ilicis Pubescentis* showed potent PDE inhibitory

activities. However, the active compounds responsible for these in vitro and in vivo activities in the extract are still unclear.

Ultrafiltration provides centrifugal force and a semipermeable membrane to separate solids and high-molecular-weight solutes from liquid and low-molecular-weight solutes. Combined with LC-MS which has become a powerful technique for simultaneous separation and identification of components, ultrafiltration LC-MS has become the state-of-the-art technique in screening and identifying active constituents in complex extracts, owing to the capability of separation of ligand-protein complexes from unbound compounds by ultrafiltration and the capability of identification of the ligands by LC-MS [17–19].

In this study, the chemical basis for the PDE inhibitory activity of *I. pubescens* roots was revealed for the first time. Nine of eleven components in *I. pubescens* roots were identified as PDE binders by the established ultrafiltration LC-MS method, five of which were further confirmed to be PDE inhibitors by in vitro inhibitory assay and quantified by HPLC. This work suggested that *I. pubescens* roots contained health beneficial compounds and can be potentially used as a functional source of medicine, soup, and/or food for the improvement of cardiac diseases.

2. Experimental

2.1. Materials and Reagents. Roots of *I. pubescens* were purchased from Guangzhou Zisun Pharmaceutical Co. Ltd. and were authenticated by Professor Shizhong Chen in the Department of Natural Medicines, Peking University. Reference powder of roots of *I. pubescens* was purchased from the National Institute for Food and Drug Control (Beijing, China). Ilexgenin A, ilexaponin A₁, ilexaponin B₁, ilexaponin B₂, chlorogenic acid, isochlorogenic acid B, and isochlorogenic acid C were obtained from Chengdu Jioute Biological Technology Co. Ltd. (Chengdu, China). The purity of each compound was determined by HPLC as above 98%. Phosphodiesterase I (PDEI) from *Crotalus adamanteus* venom (130 U/mg) was purchased from Shanghai Yuanye Bio Technology Co., Ltd. (Shanghai, China). Recombinant human PDE5A was obtained from Enzo Life Sciences, Inc. (New York, USA).

HPLC grade acetonitrile, LC-MS grade acetonitrile, and formic acid (FA) were bought from Fisher Scientific (Geel, Belgium). Analytical grade methanol (Beijing Chemical Works, Beijing, China) was used for sample preparation. Deionized water (18.2 MΩ) was prepared by a Milli-Q system (Millipore, MA, USA). Amicon® Ultra-4 10K centrifugal filter devices with maximum initial sample volume of 4.0 mL (Millipore, MA, USA) were used for sample ultrafiltration.

2.2. Sample Preparation. Roots of *I. pubescens* were pulverized into homogenized powder (number 80 mesh sieve), 5.0 g of which was accurately weighed and extracted with 50 mL of methanol in an ultrasonic water bath for 60 min. After centrifuging for 10 min at 8000 rpm, the supernatant was collected and dried by rotavapor under reduced pressure. The residue was dissolved in methanol with a concentration

of 0.1 g·mL⁻¹ (in terms of raw material). The solution was filtered through a 0.22 μm membrane readily for injection (5 μL) for LC-MS analysis.

2.3. Separating PDE Inhibitors from *I. pubescens* Roots by Ultrafiltration. The above-mentioned sample (120 μL) was diluted to 1.0 mL with 100 mM HEPES (150 mM NaCl, pH 7.4) and was then incubated with 1.0 mL of 10 U·mL⁻¹ and 20 U·mL⁻¹ PDEI in 100 mM HEPES (150 mM NaCl, pH 7.4) at 37°C for 30 min, respectively. The mixture was filtered by a centrifugal ultrafiltration device (Amicon Ultra-4 10K, cut-off molecular weight: 10 kDa) at 7500 ×g for 20 min at 25°C. The ligand-enzyme complexes on the filter were washed with 100 mM HEPES (150 mM NaCl, pH 7.4) (3 × 1 mL) by ultrafiltration. The filter was then washed with 50% methanol (3 × 0.5 mL), which was collected and dried. The residue was dissolved in 200 μL methanol, filtered through a 0.22 μm membrane before injection (20 μL) for LC-MS analysis. Solution obtained without enzyme was used as a negative control. The binding assays were carried out in triplicate (*n* = 3).

HPLC peak area enhanced as a result of incubation, which indicates binding of a ligand to PDEI. The enhancement factor (%) = $(A_1/A_2) \times 100\%$ was used for calculating the binding of a ligand to PDEI, where *A*₁ and *A*₂ are the amounts of compound bound to PDEI and the total amount of compound in incubation, respectively [17, 20].

2.4. Structural Characterization by LC-DAD-ESI-IT-TOF-MS

2.4.1. LC Conditions. Chromatographic analysis was performed on a Shimadzu HPLC system (Kyoto, Japan) including two LC-10AD pumps, a CTO-10ASvp column oven, a DGU-14A degasser, an SIL-HTC autoinjector, and an SPD-M10Avp DAD detector. Separation was carried out on an Inertsil ODS-4 C₁₈ column (5 μm, 250 mm × 4.6 mm, Shimadzu, Kyoto, Japan) maintained at 30°C. Linear-gradient elution using mobile phases A (water containing 0.1% FA) and B (acetonitrile containing 0.1% FA) was as follows: 0–2 min, 5% B; 2–40 min, 5% → 30% B; 40–60 min, 30% → 40% B; 60–75 min, 40% → 55% B; 75–85 min, 55% → 85% B; 85–90 min, 85% → 90% B. The flow rate was 1.0 mL·min⁻¹. The online UV spectra were recorded in the range of 200–400 nm, and the DAD was set at 327 nm for 0–50 min and at 210 nm for 50–90 min.

All calibration solutions were prepared by serial dilution of the individual stock solutions of the standards with methanol and filtered through a 0.22 μm membrane filter before HPLC analysis. 5 μL of each solution was injected into the HPLC system in triplicate, and a calibration curve was generated between the HPLC peak areas of compound and the concentrations for content determination. Peaks are integrated automatically by LC-MS solution software (version 3, Shimadzu, Kyoto, Japan), and the correlation coefficients were obtained using the linear regression model in Excel® (Microsoft) with all above 0.9997.

FIGURE 1: Ultrafiltration HPLC chromatograms of potential PDE inhibitors in *I. pubescens* roots. PDE I concentration: (a) 0 U·mL⁻¹; (b) 10 U·mL⁻¹; (c) 20 U·mL⁻¹; (d) crude extract of *I. pubescens* roots.

2.4.2. MS Conditions. MS analysis was performed on an IT-TOF mass spectrometer (Shimadzu LC-MS-IT-TOF, Kyoto, Japan) with an ESI interface. A full-scan MS reading in both negative and positive ion modes over the m/z range 100–1100 was performed. The CDL temperature and block heater temperature were both 200°C. The capillary voltage, CDL voltage, and detector voltage were set at 4.5 kV, 10 V, and 1.7 kV, respectively. The flow rate of nebulizer gas (N₂) was adjusted to 1.5 L·min⁻¹. During HPLC-MS analysis, the collision energy was set to 70% and the isolation width of precursor ions was 3.0 U. LC-MS solution software (version 3, Shimadzu, Kyoto, Japan) was used for data acquirement and processing.

2.5. PDE Inhibition Assay. The PDE inhibitory assay was carried out spectrophotometrically using Cyclic Nucleotide Phosphodiesterase Assay Kit (A BIOMOL® GREEN Quantizyme® Assay System, Enzo Life Sciences, Inc., New York, USA). The PDE inhibition activity was calculated as follows: inhibition (%) = $(A_1 - A_2)/A_2 \times 100$, where A_1 is the absorbance of the control and A_2 is the absorbance of the sample. The inhibitory activity was shown as the sample concentration needed to inhibit 50% of the enzymatic activity (IC₅₀).

3. Results and Discussion

3.1. LC Analysis of PDE Inhibitors after Ultrafiltration. The ultrafiltration LC-MS method can be used for the screening of bioactive compounds from complex mixtures, especially for natural products with a minimal amount of sample [21]. When the extract of *I. pubescens* roots was incubated with PDEI, potential inhibitors bound to the enzyme and unbound small molecules can be separated from the ligand-PDE complexes or PDEI by the ultrafiltration membrane. In this way, the ultrafiltration device holds active compounds bound with the receptor, while filtrating out free molecules. The binding will be affected by both the potential inhibitor and receptor concentrations. The ratio of PDEI enzyme to the root extract should be low to keep all enzyme molecules saturated by enzyme binders, while the amount of enzyme should be sufficient to absorb enough compounds for HPLC analysis. In addition, the use of highly concentrated enzyme (>50 U·mL⁻¹) would be a waste of PDEI material. In this study, the effect was evaluated by incubating a fixed concentration of the extract (0.1 g·mL⁻¹, in terms of raw material,

0.120 mL in volume) with two levels of PDEI (10 U·mL⁻¹ and 20 U·mL⁻¹, 1 mL in volume) optimized from the previous study [21]. Only compounds with certain binding ability to PDEI will be detected by LC analysis after ultrafiltration. Applying this method, nine of 11 major compounds of *I. pubescens* roots were identified as potential PDE inhibitors. Figure 1 shows the chromatograms of ultrafiltration LC analysis of *I. pubescens* root extract.

3.2. Identification of 11 Major Compounds in *I. pubescens* Roots. LC-PDA-ESI-IT-TOF-MS analysis was used to identify the 11 major compounds in *I. pubescens* roots. The mass spectral data in negative ion mode was used for characterization. The MS fragmentations of compounds together with their retention times (t_R) are summarized in Table 1. Their structures were shown in Figure 2. The ultrafiltrate was analyzed under the same condition. The retention times and MS data (see Table S1 in the Supplementary Material available online at <https://doi.org/10.1155/2017/2749643>) of the 11 compounds obtained from the ultrafiltrate were identical to those from *I. pubescens* roots extract. The EIC chromatograms of each compound in negative ion mode of the extract, ultrafiltrate, and blank sample were also shown in supplementary Figures S1–9. Compounds 1, 3, 5, 8, 9, 10, and 11 were further identified unambiguously by comparing their chromatographic and MS behaviors to corresponding standard compounds as shown in Table S1.

Peak 1 gave $[M-H]^-$ signal at m/z 353.0882 (C₁₆H₁₇O₉, error = 2.5 ppm) and a fragment ion at m/z 191 indicating the loss of caffeic acid [22–24]. It was therefore identified as chlorogenic acid [25]. Peak 2 yielded an $[M-H]^-$ ion at 579.2096 (C₂₈H₃₅O₁₃, error = 3.1 ppm) and a product ion at 417 ($[M-H-Glc]^-$) indicated the loss of a glucosyl (Glc) moiety, which further yielded an ion m/z 181 (syringyl) owing to the α,β -cleavage of the phenolic ether [26]. According to previous data [27], compound 2 was tentatively characterized as tortoside A. Peaks 3, 4, and 5 showed similar retention times (Table 1) and gave their $[M-H]^-$ ions at m/z 515.1230, 515.1190, and 515.1215 (C₂₅H₂₃O₁₂, 515.1190), respectively. The ions at m/z 179 and 191 in negative mode were deprotonated ions of caffeic acid ($[CA-H]^-$) and quinic acid ($[QA-H]^-$). Compared with standard compounds and previous reports [25, 28–32], peaks 3, 4, and 5 were thus identified as isomers of dicaffeoylquinic acid, isochlorogenic acid B, isochlorogenic acid A, and isochlorogenic acid C, respectively.

TABLE 1: Characterization of constituents by LC–ESI–IT–TOF–MS from the roots of *I. pubescens*.

Number	t_R (min)	Formula (theoretical m/z)	Experimental m/z (error, ppm)	Fragmentation	Identification
1	12.312	$C_{16}H_{18}O_9$ (353.0873)	353.0882 [$M-H$] [−] (2.5)	353 (100%) → 191 ([$M-H$ -Caffeoyl] [−])	Chlorogenic acid*
2	25.468	$C_{28}H_{36}O_{13}$ (579.2078)	579.2095 [$M-H$] [−] (2.9) 625.2131 [$M+HCOO$] [−]	579 (100%) → 417 ([$M-H$ -Glc] [−] , 100%) → 402 ([$M-H$ -Glc-CH ₃] [−]), 181 ([Syringyl] [−])	Tortoside A
3	25.630	$C_{25}H_{24}O_{12}$ (515.1190)	515.1230 [$M-H$] [−] (78)	515 (100%) → 353 ([$M-H$ -Caffeoyl] [−] , 100%) → 173 ([$M-H$ -2Caffeoyl-H ₂ O] [−]), 179 ([Caffeic acid-H] [−]), 135 ([Caffeic acid-H-CO ₂] [−])	Isochlorogenic acid B*
4	27.838	$C_{25}H_{24}O_{12}$ (515.1190)	515.1190 [$M-H$] [−] (0.0)	515 (100%) → 353 ([$M-H$ -Caffeoyl] [−] , 100%), 191 ([Quinic acid-H] [−]) → 191 ([$M-H$ -2Caffeoyl] [−])	Isochlorogenic acid A
5	29.895	$C_{25}H_{24}O_{12}$ (515.1190)	515.1215 [$M-H$] [−] (4.9)	515 (100%) → 353 ([$M-H$ -Caffeoyl] [−] , 100%), 173 ([$M-H$ -2Caffeoyl-H ₂ O] [−]) → 173 ([$M-H$ -2Caffeoyl-H ₂ O] [−])	Isochlorogenic acid C*
6	41.972	$C_{34}H_{30}O_{15}$ (677.1507)	677.1533 [$M-H$] [−] (3.8)	677 (100%) → 515 ([$M-H$ -Caffeoyl] [−] , 100%), 353 ([$M-H$ -2Caffeoyl] [−]) → 353 ([$M-H$ -2Caffeoyl] [−] , 100%), 335 ([$M-H$ -2Caffeoyl-H ₂ O] [−]) → 173 ([Quinic acid-H-H ₂ O] [−]), 179 ([Caffeic acid-H] [−]), 191 ([Quinic acid-H] [−]), 135 ([Caffeic acid-H-CO ₂] [−])	3,4,5-Tricaffeoylquinic acid
7	45.220	$C_{47}H_{76}O_{18}$ (927.4953)	927.4996 [$M-H$] [−] (4.6) 973.5043 [$M+HCOO$] [−]	927 (100%) → 765 ([$M-H$ -Glc] [−] , 100%) → 603 ([$M-H$ -2Glc] [−])	Ilexsaponin B ₃
8	56.657	$C_{47}H_{76}O_{17}$ (911.5004)	911.5049 [$M-H$] [−] (4.9) 957.5107 [$M+HCOO$] [−]	911 (100%) → 765 ([$M-H$ -Rha] [−] , 100%), 603 ([$M-H$ -GlcRha] [−]) → 603 ([$M-H$ -GlcRha] [−] , 100%) → 543 ([$M-H$ -GlcRha-H ₂ O-CO ₂] [−]), 585 ([$M-H$ -GlcRha-H ₂ O] [−])	Ilexsaponin B ₂ *
9	57.873	$C_{36}H_{56}O_{11}$ (663.3744)	663.3766 [$M-H$] [−] (3.3) 709.3860 [$M+HCOO$] [−]	663 (100%) → 501 ([$M-H$ -Glc] [−] , 100%) → 483 ([$M-H$ -Glc-H ₂ O] [−] , 100%) → 439 ([$M-H$ -Glc-H ₂ O-CO ₂] [−])	Ilexsaponin A ₁ *
10	60.828	$C_{41}H_{66}O_{13}$ (765.4425)	765.4400 [$M-H$] [−] (−3.3) 811.4497 [$M+HCOO$] [−]	765 (100%) → 603 ([$M-H$ -Glc] [−] , 100%) → 585 ([$M-H$ -Glc-H ₂ O] [−]), 543 ([$M-H$ -Glc-H ₂ O-CO ₂] [−])	Ilexsaponin B ₁ *
11	75.675	$C_{30}H_{46}O_6$ (501.3216)	501.3239 [$M-H$] [−] (4.6)	501 (100%) → 483 ([$M-H$ -H ₂ O] [−]), 439 ([$M-H$ -H ₂ O-CO ₂] [−])	Ilexgenin A*

*Compound compared with standard. Glc, glucosyl; Rha, rhamnosyl.

FIGURE 2: Structures of the 11 compounds identified in *Radix Ilicis Pubescentis*.

The $[M-H]^-$ ions of peaks **8** and **10** were at m/z 911.5049 ($C_{47}H_{75}O_{17}$, error = 4.9 ppm) and m/z 765.4400 ($C_{41}H_{65}O_{13}$, error = -3.3 ppm), respectively. They both showed m/z 603 in MS^2 which displayed the same fragmentation pattern in MS^3 , indicating their structural similarity. Compared with standards, compounds **8** and **10** were unambiguously identified as ilexsaponin B₁ and ilexsaponin B₂ [33]. Peaks **9** and **11** gave $[M-H]^-$ ions at m/z 663.3766 ($C_{36}H_{55}O_{11}$, error = 3.3 ppm) and m/z 501.3239 ($C_{30}H_{45}O_6$, error = 4.6 ppm), respectively. They shared similar fragmentation behaviors of their common ion at m/z 501. They were identified as ilexsaponin A₁ and ilexgenin A, respectively, after comparison with standard compounds and literature report [34].

Peak **7** exhibited its $[M-H]^-$ ion at m/z 927.4996 ($C_{47}H_{75}O_{18}$, error = 4.6 ppm) and $[M+HCOO]^-$ ion at m/z 973.5043 ($C_{48}H_{77}O_{20}$, error = 3.6 ppm). The ion at m/z 765 and 603 indicated the losses of two Glc moieties from the structure. According to the previous report [33], compound **7** was tentatively characterized as ilexsaponin B₃. Peak **6** showed an $[M-H]^-$ signal at m/z 677.1533 ($C_{34}H_{29}O_{15}$, error = 3.8 ppm) and yielded a product ion at m/z 515 indicating the loss of a caffeoyl group. This ion further produced ions at m/z 353 ($[M-H-2\text{caffeoyl}]^-$) and 191 ($[M-H-3\text{caffeoyl}]^-$) indicating caffeoyl substitutions on the quinic acid skeleton. In addition, its base peak at m/z 173 ($[QA-H-H_2O]^-$) and

ions at m/z 179, 191, and 135 in MS^4 , along with the presence of the fragment ion m/z 335 in MS^3 , were identical to those of 3,4-dicafeoylquinic acid [35]. Compared to the previous reports, compound **6** was thus tentatively characterized as 3,4,5-tricafeoylquinic acid [36, 37].

3.3. Validation of the PDE Inhibition Activity of Identified Compounds

3.3.1. PDE Inhibitory Activity of Active Compounds In Vitro.

To validate the activities of the identified compounds, in vitro inhibitory assays against PDEI and PDE5A were conducted using six selected compounds [isochlorogenic acid B (**3**), isochlorogenic acid C (**5**), ilexsaponin B₂ (**8**), ilexsaponin A₁ (**9**), ilexsaponin B₁ (**10**), and ilexgenin A (**11**)]. Their IC_{50} against PDEI were 779.5, 0, 853.7, 477.5, 332.0, and 837.7 μM , while those of PDE5A were 193.5, 0, 48.8, 22.4, 1801.7, and 176.6 μM , respectively, suggesting their selectivities against PDEI and PDE5A (Table 2). Dose-dependent effects were observed for all compounds except inactive isochlorogenic acid C.

3.3.2. Relative Binding Efficiency with PDEI Expressed by the Enhancement Factor. The enhancement factor (Table 2)

TABLE 2: PDE inhibitory activity (IC₅₀) and binding effect with PDEI expressed in LC signal enhancement factor of major components of *I. pubescens* roots.

Compound	Inhibitory activity (IC ₅₀ , μ M)		Enhancement factor with PDEI (%) ^a		Contents (mg/g) ^b
	PDEI	PDE5A	10 U/mL	20 U/mL	
Isochlorogenic acid B (3)	779.5	193.5	19.15 $\pm$ 0.77	25.90 $\pm$ 1.30	0.23
Isochlorogenic acid C (5)	—	—	26.73 $\pm$ 0.41	40.03 $\pm$ 0.14	0.27
Ilexsaponin B ₂ (8)	477.5	48.8	28.73 $\pm$ 0.55	41.85 $\pm$ 0.86	1.24
Ilexsaponin A ₁ (9)	332.0	22.4	11.68 $\pm$ 0.31	18.59 $\pm$ 0.65	2.53
Ilexsaponin B ₁ (10)	853.7	1801.7	9.20 $\pm$ 0.62	15.54 $\pm$ 0.21	2.18
Ilexgenin A (11)	837.7	176.6	23.08 $\pm$ 0.44	30.82 $\pm$ 0.31	8.96

^aEnhancement factor (%) = (amount of compound specifically bound)/(total amount of compound in incubation) $\times$ 100. ^bConcentration of individual compounds expressed as mg/g of dry plant powder.

was introduced to further understand the relative binding strength of each compound [17, 20]. This factor is proportional to the LC peak area of the ligand bound to the target enzyme; thus the higher factor means more bound compound. Although ilexgenin A is a predominant peak (peak 11) and with a concentration of 8.96 mg/g in the *Radix Ilicis Pubescentis* (Figure 1(d) and Table 2), its enhancement factor is less than that of ilexsaponin B₂ (8) which is the strongest PDEI ligand with a concentration of 1.24 mg/g in the sample (Figure 1(a–c)). Differently, ilexsaponin A₁ (9) with low binding efficiency turned out to be the strongest PDE inhibitor (332.0 μ M and 22.4 μ M against PDEI and PDE5A, resp.) among the components tested in vitro. Interestingly, isochlorogenic acid C (5) showed quite strong bindings to PDEI, but it was not active against PDEI and PDE5A (Table 2) indicating unspecific binding between isochlorogenic acid C and PDEI.

The validation results suggested that the ultrafiltration LC–MS is an efficient tool to screen PDE-binding active compounds, although their binding degrees did not perfectly match with their IC₅₀ values in vitro. Ilexsaponin A₁ and ilexsaponin B₂ showed stronger inhibitory activity than other constituents, suggesting that they should be considered for quality control purposes of *I. pubescens* roots for pharmaceutical use or as a functional food source.

4. Conclusion

In this study, an ultrafiltration LC–MS method was established for rapid screening potential PDE inhibitors for the first time. Nine of eleven compounds from *Radix Ilicis Pubescentis* were identified as PDE-binding active compounds by this method. Further in vitro assays confirmed the PDE inhibitory activity of components in *Radix Ilicis Pubescentis*. It is worth noting that the ultrafiltration screening method is based on the binding affinity, and the PDE binders are not necessarily the PDE inhibitors. The strong inhibitory effects of ilexsaponin A₁ and ilexsaponin B₂ against PDE5A provide further understanding of the beneficial effects of *I. pubescens* roots on cardiovascular system and also suggest that active products from natural plants/medicines can be health beneficial as edible and functional food sources. The success of this study suggested that the established approach could be a valuable tool for rapid screening of PDE inhibitors from *I. pubescens* and other complex samples.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors' Contributions

Zichen Liu and Zongtao Lin contributed equally to this work.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant nos. 81473621 and 30873397).

References

- [1] M. Conti, G. Nemoz, C. Sette, and E. Vicini, "Recent progress in understanding the hormonal regulation of phosphodiesterases," *Endocrine Reviews*, vol. 16, no. 3, pp. 370–389, 1995.
- [2] M. Zhang and D. A. Kass, "Phosphodiesterases and cardiac cGMP: evolving roles and controversies," *Trends in Pharmacological Sciences*, vol. 32, no. 6, pp. 360–365, 2011.
- [3] C. Lugnier, "PDE inhibitors: a new approach to treat metabolic syndrome?" *Current Opinion in Pharmacology*, vol. 11, no. 6, pp. 698–706, 2011.
- [4] P. Bobin, M. Belacel-Ouari, I. Bedioune et al., "Cyclic nucleotide phosphodiesterases in heart and vessels: a therapeutic perspective," *Archives of Cardiovascular Diseases*, vol. 109, no. 6–7, pp. 431–443, 2016.
- [5] W. E. Knight and C. Yan, "Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects," *Hormone and Metabolic Research*, vol. 44, no. 10, pp. 766–775, 2012.
- [6] M. Doumas, A. Lazaridis, N. Katsiki, and V. Athyros, "PDE-5 inhibitors: clinical points," *Current Drug Targets*, vol. 16, no. 5, pp. 420–426, 2015.
- [7] A. M. Henrie, J. J. Nawarskas, and J. R. Anderson, "Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review," *Core Evidence*, vol. 10, pp. 99–109, 2015.
- [8] A. Sandqvist, D. Henrohn, H. Egeröd et al., "Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension," *European Journal of Clinical Pharmacology*, vol. 71, no. 10, pp. 1165–1173, 2015.
- [9] C. C. Zhu, Z. Y. Huang, T. Q. Xiong et al., "Effect of different extraction fractions of radix ilicis pubescentis on cardiovascular system," *Traditional Chinese Drug Research & Clinical Pharmacology*, vol. 22, no. 3, pp. 249–252, 2011.
- [10] Z.-H. Jiang, J.-R. Wang, M. Li et al., "Hemiterpene glucosides with anti-platelet aggregation activities from *Ilex pubescens*," *Journal of Natural Products*, vol. 68, no. 3, pp. 397–399, 2005.
- [11] S. W. Zhang and S. X. Xian, "Clinical study of anti-inflammation action of radix ilicis pubescentis in chronic heart failure patients," *Journal of Guangzhou University of Traditional Chinese Medicine*, vol. 29, no. 2, pp. 120–123, 2012.
- [12] M.-S. Miao, L. Guo, R.-Q. Li, and X. Ma, "Radix *Ilicis Pubescentis* total flavonoids combined with mobilization of bone marrow stem cells to protect against cerebral ischemia/reperfusion injury," *Neural Regeneration Research*, vol. 11, no. 2, pp. 278–284, 2016.
- [13] J. Jin, C.-Y. Qin, Y. Zhou, R.-X. Zeng, and Z.-X. Zhao, "Preparation of triterpenoid ilexoside O from *Ilex pubescens* and study on its antithrombotic activity," *Chinese Traditional and Herbal Drugs*, vol. 45, no. 13, pp. 1834–1837, 2014.
- [14] Y. Zhou, S.-X. Zhou, Y. Jiang, J. Sun, and P.-F. Tu, "Chemical constituents in leaves of *Ilex pubescens*," *Chinese Traditional and Herbal Drugs*, vol. 43, no. 8, pp. 1479–1483, 2012.
- [15] Y. Xiong, C. Li, and X. Luo, "Advances in the study of *Ilex pubescens* Hook. et Arm: chemical constituents and pharmacological action," *Zhong Yao Cai*, vol. 25, no. 5, pp. 371–374, 2002.
- [16] L. Meng, J. Chen, J. Sun et al., "Effect of radix ilicis pubescentis on rat ventricular remodeling and cardiac function of chronic heart failure rats," *Traditional Chinese Drug Research & Clinical Pharmacology*, vol. 23, no. 4, pp. 435–437, 2012.

- [17] L. Li, B. Li, H. R. Zhang et al., "Ultrafiltration LC-ESI-MSⁿ screening of MMP-2 inhibitors from selected Chinese medicinal herbs *Smilax glabra* Roxb., *Smilax china* L. and *Saposhnikovia divaricata* (Turcz.) Schischk as potential functional food ingredients," *Journal of Functional Foods*, vol. 15, pp. 389–395, 2015.
- [18] H. Zhao, Y. Zhang, Y. Guo, and S. Shi, "Identification of major α -glucosidase inhibitors in *Radix Astragali* and its human microsomal metabolites using ultrafiltration HPLC-DAD-MSn," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 104, pp. 31–37, 2015.
- [19] S. Liu, J. Yan, J. Xing, F. Song, Z. Liu, and S. Liu, "Characterization of compounds and potential neuraminidase inhibitors from the n-butanol extract of Compound Indigowoad Root Granule using ultrafiltration and liquid chromatography-tandem mass spectrometry," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 59, no. 1, pp. 96–101, 2012.
- [20] A. Zhao, L. Li, B. Li, M. Zheng, and R. Tsao, "Ultrafiltration LC-ESI-MSn screening of 5-lipoxygenase inhibitors from selected Chinese medicinal herbs *Saposhnikovia divaricata*, *Smilax glabra*, *Pueraria lobata* and *Carthamus tinctorius*," *Journal of Functional Foods*, vol. 24, pp. 244–253, 2016.
- [21] S.-Y. Shi, M.-J. Peng, Y.-P. Zhang, and S. Peng, "Combination of preparative HPLC and HSCCC methods to separate phosphodiesterase inhibitors from *Eucommia ulmoides* bark guided by ultrafiltration-based ligand screening," *Analytical and Bioanalytical Chemistry*, vol. 405, no. 12, pp. 4213–4223, 2013.
- [22] M. Liu, J. Dong, Z. Lin et al., "Rapid screening of transferrin binders in the flowers of *Bauhinia blakeana* Dunn by on-line high-performance liquid chromatography-diode-array detector-electrospray ionization-ion-trap-time-of-flight-mass spectrometry-transferrin-fluorescence detection system," *Journal of Chromatography A*, vol. 1450, pp. 17–28, 2016.
- [23] S. Li, Z. Lin, H. Jiang, L. Tong, H. Wang, and S. Chen, "Rapid identification and assignment of the active ingredients in fufang banbianlian injection using HPLC-DAD-ESI-IT-TOF-MS," *Journal of Chromatographic Science*, vol. 54, no. 7, pp. 1225–1237, 2016.
- [24] Y. Niu, S. Li, Z. Lin et al., "Development of propidium iodide as a fluorescence probe for the on-line screening of non-specific DNA-intercalators in Fufang Banbianlian Injection," *Journal of Chromatography A*, vol. 1463, pp. 102–109, 2016.
- [25] M. N. Clifford, K. L. Johnston, S. Knight, and N. Kuhnert, "Hierarchical scheme for LC-MSn identification of chlorogenic acids," *Journal of Agricultural and Food Chemistry*, vol. 51, no. 10, pp. 2900–2911, 2003.
- [26] P. C. Eklund, M. J. Backman, L. Å. Kronberg, A. I. Smeds, and R. E. Sjöholm, "Identification of lignans by liquid chromatography-electrospray ionization ion-trap mass spectrometry," *Journal of Mass Spectrometry*, vol. 43, no. 1, pp. 97–107, 2008.
- [27] C. Z. Wang and Z. J. Jia, "Lignan, phenylpropanoid and iridoid glycosides from *Pedicularis torta*," *Phytochemistry*, vol. 45, no. 1, pp. 159–166, 1997.
- [28] H. Sun, M. Liu, Z. Lin et al., "Comprehensive identification of 125 multifarious constituents in Shuang-huang-lian powder injection by HPLC-DAD-ESI-IT-TOF-MS," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 115, pp. 86–106, 2015.
- [29] Q. Fu, C. Zhang, Z. Lin et al., "Rapid screening and identification of compounds with DNA-binding activity from *Folium Citri Reticulatae* using on-line HPLC-DAD-MS(n) coupled with a post column fluorescence detection system," *Food Chemistry*, vol. 192, pp. 250–259, 2016.
- [30] X. Zhang, Z. Lin, J. Fang et al., "An on-line high-performance liquid chromatography-diode-array detector-electrospray ionization-ion-trap-time-of-flight-mass spectrometry-total antioxidant capacity detection system applying two antioxidant methods for activity evaluation of the edible flowers from *Prunus mume*," *Journal of Chromatography A*, vol. 1414, pp. 88–102, 2015.
- [31] C. Zhang, B. Ren, Z. Lin, L. Tong, H. Wang, and S. Chen, "An analysis method for simultaneous screening of deoxyribonucleic acid-binding active compounds and investigating their mechanisms by ultra-fast liquid chromatography tandem mass spectrometry coupled with fluorescence detection technology," *Journal of Chromatography A*, vol. 1381, pp. 160–172, 2015.
- [32] S. Li, H. Jiang, Z. Lin et al., "An on-line high-performance liquid chromatography-diode-array detector-multi-stage mass spectrometry-deoxyribonucleic acid-4',6-diamidino-2-phenylindole-fluorescence detector system for screening the DNA-binding active compounds in Fufang Banbianlian Injection," *Journal of Chromatography A*, vol. 1424, pp. 37–50, 2015.
- [33] K. Hidaka, M. Ito, and Y. Matsuda, "New triterpene saponins from *Ilex pubescens*," *Chemical and Pharmaceutical Bulletin*, vol. 35, no. 2, pp. 524–529, 1987.
- [34] J. Yamahara, K. Hidaka, M. Ito, Y. Matsuda, H. Kohda, and K. Yamasaki, "A triterpene and saponin from roots of *Ilex pubescens*," *Phytochemistry*, vol. 26, no. 7, pp. 2023–2027, 1987.
- [35] I. Parveen, M. D. Threadgill, B. Hauck, I. Donnison, and A. Winters, "Isolation, identification and quantitation of hydroxycinnamic acid conjugates, potential platform chemicals, in the leaves and stems of *Miscanthus × giganteus* using LC-ESI-MSn," *Phytochemistry*, vol. 72, no. 18, pp. 2376–2384, 2011.
- [36] L.-Z. Lin and J. M. Harnly, "Identification of hydroxycinnamoylquinic acids of arnica flowers and burdock roots using a standardized LC-DAD-ESI/MS profiling method," *Journal of Agricultural and Food Chemistry*, vol. 56, no. 21, pp. 10105–10114, 2008.
- [37] R. Jaiswal and N. Kuhnert, "Hierarchical scheme for liquid chromatography/multi-stage spectrometric identification of 3, 4,5-triacetyl chlorogenic acids in green Robusta coffee beans," *Rapid Communications in Mass Spectrometry*, vol. 24, no. 15, pp. 2283–2294, 2010.